| 入世--中国制药业的又一春 |
| |
| 引用本文： | 彭浩东,黄惠平.入世--中国制药业的又一春[J].中国卫生事业管理,2002,18(5):264-266. |
| |
| 作者姓名： | 彭浩东 黄惠平 |
| |
| 作者单位： | 1. 中国药科大学社科部,210009
2. 南京大学国际商学院,210093 |
| |
| 摘 要： | 加入 WTO对中国制药业利大于弊。本文认为加入 WTO有利于中国制药企业以更积极的姿态迎接市场竞争 ;有利于我国制药企业由仿制型向自主开发型转化 ;有利于我国制药企业向集团化方向发展 ;有利于我国中药现代化。
|
| 关 键 词： | 仿制 新药穷国 集团化 |
| 文章编号： | 1004-4663(2002)05-0264-03 |
| 修稿时间： | 2001年11月15 |
Joining in WTO-Another Spring for Medicine Industry in China |
| |
| Peng Haodong,et al..Joining in WTO-Another Spring for Medicine Industry in China[J].Chinese Health Service Management,2002,18(5):264-266. |
| |
| Authors: | Peng Haodong |
| |
| Institution: | Peng Haodong,et al.Department of Social Science,China Pharmacy University,Nanjing,Jiangsu Province P.R. China |
| |
| Abstract: | There will be more advantages than disadvantages for medicine industry after China joins in WTO. The advantages include: (1) Chinese medicine industry will take part in the market competition with more active attitude; (2) it is helpful for medicine industry changing from imitation to exploitation; (3) it is helpful for medicine industry's group development; and (4) it will promote modernization of Traditional Chinese Medicine. |
| |
| Keywords: | Imitation New medicine Group |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
